Efficacy and safety of long-term bisphosphonates in postmenopausal osteoporosis

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 12, 2003, Pages 2253-2258

  Miller, Paul D ^a  

^a University of Colorado Health Sciences Center   (United States)

Author keywords

Bisphosphonate efficacy; Bisphosphonate safety; Duration of bisphosphonate use; Osteoporosis treatment

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; ETIDRONIC ACID; RISEDRONIC ACID;

AGED; BONE DENSITY; BONE MINERAL; DRUG ADMINISTRATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FEMALE; FRACTURE; GASTROINTESTINAL SYMPTOM; HIGH RISK POPULATION; HUMAN; LONG TERM CARE; MORPHOMETRICS; OSSIFYING MYOSITIS; OSTEOLYSIS; POSTMARKETING SURVEILLANCE; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; VERTEBRA FRACTURE;

AGED; BONE DENSITY; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; FEMALE; FRACTURES, BONE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; RISK FACTORS;

EID: 0347627455     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.4.12.2253     Document Type: Review

References (40)

1. RUSSELL RG, SMITH R, PRESTON C et al.: Diphosphonates in Paget's Disease. Lancet (1974) 1:894-896.
2. WATTS NB, HARRIS ST, GENANT HK et al.: Intermittent cyclical etidronate tratement of postmenopausal osteoporosis. New Engl. J. Med. (1990) 323:73-79.
3. BLACK DM, CUMMINGS SR, KARPF DB et al.: Randomized trial of the effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet (1996) 348(1):535-541.
4. HARRIS S, WATTS NB, GENANT HK et al.: Effects of risedronate on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. A randomized controlled trial. JAMA (1999) 282:1344-1352.
5. CUMMINGS SR, BLACK DM, THOMPSON D et al.: Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. Results from the Fracture Intervention Trial. JAMA (1998) 280:2077-2082.
6. REGINSTER J-Y, MINNE H, SORENSEN OH et al.: Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos. Int. (2000) 11:83-91.
7. MCCLUNG M, GEUSENS P, MILLER PD et al.: Effect of risedronate on the risk of hip fracture in the elderly. N. Engl. J. Med. (2001) 344:333-340.
8. MCCLUNG MR, CLEMMESEM B, DAIFOTIS A et al.: Alendronate prevents postmenopausal bone loss in women without osteoporosis. Ann. Intern. Med. (1998) 128:253-261.
9. FOGELMAN I, RIBOT C, SMITH R et al.: Risedronate reverses bone loss in postmenopausal women with low bone mass: results ftorn a multi-national, double-blind, placebo-controlled trial. J. Clin. Endocrinol. Metab. (2002) 85:1895-1900.
10. ROSSOUW JE, ANDERSON GL, PRENTICE RL et al.: Writing group for the women's health initiative investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA (2002) 288:321-333.
11. SHUMAKER SA, LEGAULT C, THAL L et al.: Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study; a randomized controlled trial. JAMA (2003) 289:2651-2662.
12. SIRIS E, MILLER PD, BARRETT-CONNER E et al.: Identification and fracture outcomes of undiagnosed low bone density in postmenopausal women: results from The National Osteoporosis Risk Assessment (NORA). JAMA (2001) 286:2815-2822.
13. BARRETT-CONNOR E, WEHREN LE, SIRIS ES et al. Recency and duration of postmenopausal hormone therapy: effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA) study. Menopause (2003) 10(5):412-419.
14. SORENSEN OH, CRAWFORD GM, MULDER H et al.: (2003) Long-term effect of risedronate: a 5 year placebo-controlled clinical experience. Bone 32:120-126.
15. TONINO RP, MEUNIER PJ, EMKEY R et al.: Skeletal effects of alendronate: 7 year treatment of postmenpausal women. Phase III. J. Clin. Endocrinol. Metab. (2000) 85:3109-3115.
16. EMKEY R, REID I, MULLOY A et al.: Ten-year efficacy and safety of alendronate in the treatment of osteoporosis in postmenopausal women. J. Bone Miner. Res. (2002) 17(Suppl. 1):S139.
17. SORENSON OH, KAUFMAN JM, WENDEROTH D et al.: Sustained effect of risedronate: a 7-year study in postmenopausal women. J. Clin. Densit. (2003) 6(2):191.
18. WASNICH RD AND MILLER PD: Antifracture efficacy of antiresorptive agents are related to changes in bone density. J. Clin. Endocrinol. Metab. (2001) 85:231-236.
19. CUMMINGS SR, KARPF DB, HARRIS F, GENANT HK, ENSRUD K, LACROIX AZ, BLACK D: Improvements in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am. J. Med. (2002) 114:281-289.
20. HOCHBURG MC, GREENSPAN S, WASNICH RD, MILLER PD, THOMPSON DE, ROSS PD: Changes in bone density and turnover explain the reductions in incidence of non-vertebral fractures that occur during treatment with antiresorptive agents. J. Clin. Endocrinol. Metab. (2002) 87:1586-1592.
21. RODAN GA: Mechanisms of action of bisphosphonates Ann. Rev. Pharamacol. Toxicol. (1998) 38:375-388.
22. RUSSELL RG AND ROGERS MJ: Bisphosphonates: from the laboaratory to the clinic and back again. Bone (1999) 25:97-106.
23. VITTE C, SLEISCH H, GUENTHER HL: Bisphosphonates induce osteoblasts to secrete and inhibitor of osteoclast-mediated bone resorption. Endocrinology (1996) 137:324-333.
24. WEINSTEIN RS, MANOLAGAS S: Apoptosis and osteoporosis. Am. J. Med. (2000) 108(2):153-164.
25. MASHIBA T, TURNER CH, HORANO T et al.: Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles Bone (2001) 28:524-531.
26. LI J, MASHIBA T, BURR DB: Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage. Calcif. Tissue Int. (2001) 69(5):281-286.
27. CHAVASSIEUX PM, ARLOT ME, REDA C et al.: Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J. Clin. Invest. (1997) 100:1475-1480.
28. ERIKSEN E, MELSEN S, SOD E et al.: Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone (2002) 31(5):620-625.
29. DING M, DAY JS, BURR DB et al.: Canine cancellous bone microarchitecture after one year of high-dose bisphosphonates. Calcif. Tissue Int. (2003) 72:737-744.
30. MILLER PD: Analsysis of 1-year vertebral fracture risk reduction data in treatments for osteoporosis. Southern Med. Assoc. J. (2003) 96:478-485.
31. COCO M, RUSH H: Increased incidence of hip fractures in dialysis patients with PTH levels in the adynamic range. Am. J. Kid. Dis. (2001) 36:1115-1121.
32. WEINSTEIN RS: Perspective: true strength. J. Bone Miner. Res. (2000) 15:621-625.
33. MILLER PD, WATTS NB, LICATA AA et al.: Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after 7 years of treatment. Am. J. Med. (1997) 103:468-478.
34. GREENSPAN S, EMKEY R, BONE HG 3rd et al.: Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. Ann. Intern. Med. (2002) 137:875-883.
35. RAVN P, WEISS SR, RODRIGUEZ-PORTALES JA et al.: Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawl. J. Clin. Endocrinol. Metab. (2000) 85:1492-1497.
36. MORTENSEN L, CHARLES P, BEKKER PJ et al.: Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up. J. Clin. Endocrinol. Metab. (1998) 83:396-402.
37. NANCOLLAS G, TANG R, ROGERS MJ et al.: Mineral binding affinities of bisphosphonates. J. Bone Miner. Res. (2002) 17:368-372.
38. KAHN SA, KANIS JA, VASIKARAN S et al.: Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J. Bone Miner. Res. (1997) 12:1700-1707.
39. EASTELL R, BARTON I, HANNON RA et al.: Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J. Bone Miner. Res. (2003) 18:1051-1056.
40. BORAH B, DUFRENSE TE, CHMIELEWSKI PA et al.: Risedronate preserves bone architecture in osteoporotic postmenopausal womenas measured by 3-DF micro-computed tomography. J. Bone Miner. Res. (2002) 17:1139-1145.